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Abstract
Background: The presence of a fragility fracture is a major risk factor for osteoporosis, and
should be an indicator for osteoporosis diagnosis and therapy. However, the extent to which
patients who fracture are assessed and treated for osteoporosis is not clear.
Methods: We performed a review of the literature to identify the practice patterns in the
diagnosis and treatment of osteoporosis in adults over the age of 40 who experience a fragility
fracture in Canada. Searches were performed in MEDLINE (1966 to January 2, 2003) and CINAHL
(1982 to February 1, 2003) databases.
Results: There is evidence of a care gap between the occurrence of a fragility fracture and the
diagnosis and treatment of osteoporosis in Canada. The proportion of individuals with a fragility
fracture who received an osteoporosis diagnostic test or physician diagnosis ranged from 1.7% to
50%. Therapies such as hormone replacement therapy, bisphosphonates or calcitonin were being
prescribed to 5.2% to 37.5% of patients. Calcium and vitamin D supplement intake was variable,
and ranged between 2.8% to 61.6% of patients.
Conclusion: Many Canadians who experience fragility fracture are not receiving osteoporosis
management for the prevention of future fractures.
Background
Osteoporosis has been described as a silent disease until
an individual experiences a fragility fracture, typically
occurring at the wrist, vertebra or the hip. The National
Institutes of Health consensus conference has modified
the original definition of osteoporosis to include "a skele-
tal disorder characterized by compromised bone strength,
predisposing a person to an increased risk of fracture.
Bone strength reflects the integration of two main features
bone density and bone quality" [1].
A fragility fracture is a major risk factor for osteoporosis,
and has been identified as the only clinically relevant
marker of bone quality. These fractures typically occur
when an individual falls from a standing height or less.
However vertebral and rib fractures often occur without a
traumatic event such as during coughing [2]. A history of
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fragility fracture after the age of 40 years increases the risk
of a subsequent fracture by 2- to 9-fold [3,4]. Therapeutic
options, such as raloxifene, alendronate, risedronate, can
reduce the number of new vertebral compression fractures
by 40–60% within the first year in individuals with a frac-
ture [5]. It is important to identify whether patients who
experience fragility fracture are being assessed and treated
for osteoporosis in order to reduce the risk of future
fracture.
Inadequate osteoporosis evaluation and treatment fol-
lowing fragility fracture has been documented in coun-
tries other than Canada [6-13]. A large retrospective
cohort study in the United States found that only 2.8% of
women who had experienced a distal radius fracture
underwent densitometry and 22.9% of the women were
prescribed osteoporosis treatment [7]. Between 1997 and
2000 in an American retrospective cohort study, only 13%
of those who had experienced hip fractures received sup-
plemental calcium, and 6% actually received an anti-
resorptive medication [8].
If an osteoporosis care gap exists, it is essential that pri-
mary care physicians and specialists be made aware of it
in order to improve the standard of care. The purpose of
this review is to identify the practice patterns in the diag-
nosis and treatment of osteoporosis in adults over the age
of 40 who experience a fragility fracture in Canada.
Methods
In order to identify articles that evaluated osteoporosis
diagnosis and treatment after fragility fracture in Canada,
a literature search was performed in MEDLINE (1966 to
January 2, 2003) and CINAHL (1982 to February 1, 2003)
databases, using the key words osteoporosis [Diagnosis,
Prevention and Control, Diet Therapy, Drug Therapy, Sur-
gery, Therapy]; hip fractures; femoral fractures; radius frac-
tures; spinal fractures; and Canada. Additional articles
were identified by consultation with experts and hand
searching of the references of retrieved articles.
Selection criteria for retrieved articles included an evalua-
tion of the diagnosis and/or initiation of treatment for
osteoporosis in individuals over the age of 40 years after
experiencing a fragility fracture. A physician's clinical
diagnosis and/or dual-energy x-ray absorptiometry (DXA)
were recorded as osteoporosis diagnosis outcomes. Treat-
ment outcomes included calcium, vitamin D, hormone
replacement therapy (HRT), bisphosphonates (etidro-
nate, alendronate, risedronate), calcitonin, and selective
estrogen receptor modulators (raloxifene). Studies were
excluded if fractures were a result of malignancy or
trauma. The proportion of patients receiving an oste-
oporosis diagnosis and/or each form of treatment was
recorded.
Using the above search strategy, ten articles were identi-
fied, one of which met the a priori selection criteria. Two
articles were identified via consultation with experts, and
another was included after hand searching the reference
lists. In order to provide a description of the quality of the
studies, a list of questions were derived based on some of
the quality criteria for assessment of observational studies
outlined previously [14].
Results
The characteristics of the included studies are listed in
Table 1. Four studies met the inclusion criteria, and the
patient characteristics are listed in Table 2. These studies
included patients, aged 50–97 years, discharged from
acute care [15-17] and fracture clinics [18] in major urban
centres with access to bone densitometry and osteoporo-
sis specialists. In all studies, patients were selected by the
reviewing of medical records to identify individuals who
fractured. The sample sizes for each study were not deter-
mined a priori, but based on the number of individuals
identified in the medical records that agreed to partici-
pate. In the fracture clinic study, the most common type
of fracture was wrist fracture (77.3%), and of these, 72.4%
were deemed to be fragility fractures. Vertebral fractures
comprised 0.5% of the number of fractures seen at a frac-
ture clinic [18]. Two studies of hip fractures in acute care
settings revealed that only 1.7% to 14.5% of those with
fracture received a diagnosis of osteoporosis [17]. Up to
40% of patients had experienced a prior fragility fracture
when they were initially identified (index fracture). Subse-
quent fractures within 1–3 years occurred in up to 14% of
patients. The criteria used to make a diagnosis of oste-
oporosis varied across studies, from the use of densitom-
etry to the presence of a fragility fracture (Table 3). The
proportion of individuals who had a clinical diagnosis of
osteoporosis or a bone mineral density test ranged from
1.7% to 50%, depending on the type of fracture.
Calcium supplements were cited as osteoporosis treat-
ment in 7.6% to 32% of patients after fracture. Only 2.8%
to 13% of patients were taking vitamin D [15,18]. In some
cases authors did not differentiate between calcium, vita-
min D, or multivitamin use [16,17]. HRT or bisphospho-
nates were prescribed less frequently. One study indicated
that 1.4% of women were taking HRT [19]. Individuals on
bisphosphonates ranged from 5.2% to 16% [15,18]. A
study of wrist fractures that did not differentiate between
osteoporosis-specific therapies reported that 37.5% were
taking some form of treatment [16].
Discussion
These studies provide evidence that many Canadians who
experience fragility fracture are not being diagnosed or
treated for the prevention of future fractures. The preva-
lence of bone mass measurements or physician follow-upBMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/11
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among individuals experiencing a fragility fracture was
less than 50%, in most cases, much less. Fifty to 98.3% of
individuals who experience a fragility fracture received no
treatment for osteoporosis. Vitamin D supplement pre-
scription was low despite research indicating that as many
as 34% of Canadians are deficient (<40 nmol/L) [20].
Unfortunately, many individuals who fracture were not
assessed or treated for osteoporosis. At the time the stud-
ies were conducted, bisphosphonates and HRT were rec-
ommended therapies for the treatment of osteoporosis
however, only a small proportion of patients with fragility
fracture were prescribed these medications. The following
therapies were available for prescription in 1995: etidro-
nate as of July 1995, alendronate as of December of 1995,
and calcitonin was also available during the time the stud-
ies were reviewed. Raloxifene became available in Canada
in January of 1999.
Table 1: Study Design Characteristics
Hajcsar (2000)18 Papaioannou (2000)17 Khan (2001)16 Juby (2002)15
Setting Three Ontario Community 
Hospital Fracture Clinics
Four Tertiary Care Hospitals, 
Hamilton
One Tertiary Care Hospital, 
Edmonton
One Tertiary Care Hospital, 
Edmonton
Sample 56.1% of patients with fragility 
fracture
All patients with hip fracture 72% of patients with fragility 
fracture of distal radius/ulna
All patients with new hip 
fracture
Participant Selection Medical records Medical records Medical records Medical records
Inclusion Criteria Age > 18 years No secondary 
causes of bone loss, no significant 
trauma
Age ≥ 50 years, Hip fracture, not 
hospitalized for motor vehicle 
accident or malignancy
Age > 40 years, No significant 
trauma
Age > 65 years, New hip 
fracture
When were participants 
assessed?
1 year post-fracture Acute care records and 1 year post-
fracture
6 months to 3 years post-
fracture
Acute care and after 
rehabilitation
How were outcomes 
determined?
Telephone interview Medical records and telephone 
interview
Telephone interview Medical records
Table 2: Patient Characteristics
Study Patients Fracture Type Prior Fracture, Subsequent Fracture
Hajcsar (2000)18 N = 108 (89%F, 11%M)
Mean age: 64 yrs
77.3% Wrist
6.3% Hip
0.5% Vertebrae
15.9% Humerus
Prior fracture: 43 (39.8%)
Subsequent fracture 1 year post: 3 (2.8%)
Papaioannou(2000)17 N = 504 (75%F, 25%M)
Mean age F: 81.5
Mean age M: 75.7
Hip Subsequent fracture 1 year post: 50 (9.9%)
Khan (2001)16 N = 112 (83%F, 17%M)
Mean age: 64 ± 13 yrs
Wrist Prior fracture: 44 (39%)
Subsequent fracture 6 months to 3 years post: 16 (14%)
Juby (2002)15 N = 293 (73%F, 27%M)
Mean age: 85.7 yrs (66–97)
Hip Prior hip fracture: 54 (18.4%)
Table 3: Prevalence of osteoporosis diagnoses and treatment in patients who have sustained a fragility fracture
Hajcsar (2000)18 Papaioannou (2000)17 Khan (2001)16 Juby (2002)15
Diagnosis (%)
Clinical Diagnosis 18.5 1.7 - 14.5
Densitometry 22.2 - - 3
Either of above - - 50 -
Treatment (%)
Calcium 32.4 - - 7.6
V i t a m i n  D 1 3 . 0 --2 . 8
Calcium and/or Vit D - 4.7 61.6 -
HRT 16 0 - 1.4
Bisphosphonates 7.4 0 - 5.2
Any osteoporosis-specific 
therapy
- - 37.5 9.7BMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/11
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Access to technology may present a barrier to osteoporosis
diagnosis. The most commonly cited limitations to the
use of densitometry in a survey of Ontario family physi-
cians included the distance to the nearest densitometry
facility and the cost of the test. However, the survey did
note that physicians were following the guidelines for
densitometry use where it was available [21]. In contrast,
a study performed in Alberta demonstrated low use of
densitometry for the prevention and treatment of oste-
oporosis in postmenopausal women, citing physician atti-
tudes as important factors in decisions about screening
and treatment [22]. A larger number of densitometry facil-
ities exist in Ontario as compared to other provinces [21].
A lack of access to bone mineral density testing may play
a greater role in an osteoporosis care gap in the remainder
of Canada.
Although the diagnosis of osteoporosis after fragility frac-
ture is important, it can only be effective in preventing
future fracture if it leads to subsequent treatment of
patients at risk. The proportion of postmenopausal
women at an Ottawa hospital receiving osteoporosis ther-
apy increased from 15.2% to 63.3% after a diagnosis of
osteoporosis with densitometry [23]. Hip fracture patients
in Alberta who were diagnosed with osteoporosis post-hip
fracture were more likely to receive treatment (48% vs.
5.5%) [15]. In three British Columbia long-term care facil-
ities, the mean calcium and vitamin D intake of those who
had been diagnosed with osteoporosis met the 'adequate
intake' level (1200 mg calcium, 600 IU vitamin D), com-
pared to those without an osteoporosis diagnosis. In addi-
tion, those residents who had an osteoporosis diagnosis
were more likely to have been prescribed bisphospho-
nates or HRT than those who had fractured but had not
been diagnosed with osteoporosis [24]. These studies
highlight the importance of a diagnosis of osteoporosis
for future fracture prevention in those individuals who
have experienced a fragility fracture.
A key message is that a prior fragility fracture is a major
risk factor for subsequent fracture. The prevalence of a
prior fracture in the articles we reviewed ranged from 18.4
to 40% of patients [15,16,18]. In the United States, 45%
of women admitted with fragility fracture had experienced
at least one prior fracture, one fourth of which were hip
fractures [12]. Another study documented that 33% of
women admitted with distal forearm fracture had had a
prior fracture [25]. The high risk of future fracture among
the patients in the studies we reviewed was illustrated by
the findings of a subsequent fracture in up to 14% of indi-
viduals. One study of women with hip fracture in the
United States reported an incidence of 22% for any type
of future fragility fracture [26]. These phenomena also
occur in men. In one study, 30% of male veterans admit-
ted with hip fracture had experienced a prior history of a
fragility fracture, and 10% went on to experience a subse-
quent fracture [11]. It is essential that fragility fractures are
identified as a risk factor for future fractures, and appro-
priate treatment measures are taken to reduce this risk
[3,4].
These conclusions are limited by the lack of prospective
epidemiologic data. Chart reviews may miss data that
were not recorded and patient interviews rely on patient
recall, which can be inaccurate. In addition, the studies
may only be representative of tertiary care centres. The
studies attempted to include representative samples of
patients experiencing fragility fracture. The community-
based hospital study included the smallest proportion
(56.1%), where most patients who were not included
could not be reached, and a small number declined to par-
ticipate. Another concern is that women may have been
prescribed HRT for reasons other than osteoporosis, again
pointing to the potential for over estimation of those diag-
nosed with osteoporosis and treated after fragility fracture.
The study was limited to Canadian studies in order to
avoid bias related to differences in the provision of health
care services and/or available technologies. A survey of
physicians in the United States, Canada and West Ger-
many revealed that 73 percent of physicians in the U.S.
reported that patients' inability to afford treatment was a
serious problem, compared with only 25 percent in Can-
ada and 15 percent in West Germany [27]. Future research
should evaluate the whether an osteoporosis care gap is an
international phenomenon. Finally, the studies reviewed
are several years old, and it is possible that practice pat-
terns may be improving.
Conclusion
The main message of this review is that despite the availa-
bility of a number of therapeutic options, many patients
with fragility fracture do not undergo osteoporosis man-
agement, and are at high risk for subsequent fractures. The
existing care gap between the occurrence of a fragility frac-
ture and the diagnosis and treatment of osteoporosis
requires multi-faceted intervention, such as a model for
disease management, in order to reduce the incidence of
fracture. Future research and education approaches
should include strategies to address the barriers identified
by family physicians and specialists in the diagnosis and
treatment of osteoporosis, which include a lack of ration-
ale for bone mineral density testing and confusion about
management [28]. Improved communication between
orthopaedic surgeons, specialists and family physicians
with respect to patient follow-up may reduce the gap
between fracture occurrence and osteoporosis manage-
ment. In addition, strategies to involve the patient may be
useful. Educational tools may aid patients in seeking oste-
oporosis screening from their physicians [29]. A paradigm
shift is warranted, such that individuals over 40 years ofBMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/11
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age who present with fragility fracture should trigger a
process of osteoporosis diagnosis and treatment in order
to reduce the risk of another fracture in the future.
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